It is suggested that the CRIF1–CDK2 interface inhibitor could improve cellular radio sensitivity in the osteosarcoma (OS) cell lines by selectively enhancing arrest in the G2/M phase and apoptosis associated with CDK2 overactivation in these cells [16]. This evidence concerns the gene CDK2 and osteosarcoma.